Identification of potential inhibitors for identified novel drug targets of Aspergillus fumigatus

Aspergillosis is the most common mold infection worldwide and Aspergillus fumigatus is the most common etiological agent being responsible for approximately 90% of human infections. Over the past years, A. fumigatus has become the most prevalent airborne fungal pathogen, causing severe and usually fatal invasive infections in immune compromised hosts in developed countries. Despite the prevalence of life-threatening fungal infections by Aspergillus fumigatus, treatments are restricted to a relatively few antifungal drugs whose use is increasingly challenged by the emergence of drug- resistant fungi and by serious problems of toxicity. An urgent need exists for a novel drug target and the new generation of antifungal drugs with superior safety and efficacy against a broad fungal spectrum. In this paper, the subtractive genomic approach was used to identify novel drug target for Aspergillus fumigatus. Out of 51,215 protein in Aspergillus fumigatus only 3,805 protein remains after excluding homologous protein. In this paper, we finally find out two novel drug target after performing modelling and then identified its potential inhibitor with the help of screening and docking.